Immunome (IMNM) Cash from Investing Activities (2019 - 2026)

Immunome (IMNM) has 8 years of Cash from Investing Activities data on file, last reported at -$12.0 million in Q1 2026.

• Quarterly Cash from Investing Activities fell 336.12% year-over-year to -$12.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $43.7 million (up 202.23% YoY) and the FY2025 annual result came in at $60.8 million, up 171.48% from the prior year.
• Cash from Investing Activities eased to -$12.0 million in Q1 2026, from -$4.0 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $123.9 million in Q3 2025 to a low of -$81.7 million in Q2 2024.
• A 5-year average of -$4.2 million and a median of -$138000.0 in 2022 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2023 — Cash from Investing Activities plunged 41569.44% — and 2024, when it surged 67038.89%.
• Tracing IMNM's Cash from Investing Activities over 5 years: stood at -$72000.0 in 2022, then sank by 41569.44% to -$30.0 million in 2023, then jumped by 132.52% to $9.8 million in 2024, then sank by 140.98% to -$4.0 million in 2025, then plunged by 200.48% to -$12.0 million in 2026.
• The last three Cash from Investing Activities figures came in at -$12.0 million (Q1 2026), -$4.0 million (Q4 2025), and $123.9 million (Q3 2025), per Business Quant data.